Drug Profile
SER 130
Alternative Names: Ph8; SER-130; SER-130-AMILatest Information Update: 25 Jan 2021
Price :
$50
*
At a glance
- Originator Phlogo
- Developer Serodus
- Class Anti-inflammatories; Peptides
- Mechanism of Action Interleukin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diabetic nephropathies
- Discontinued Diabetic retinopathy; Myocardial infarction
Most Recent Events
- 20 Jan 2021 SER 130 is available for licensing as of 20 Jan 2021. https://serodus.com/partnering/
- 20 Jan 2021 Discontinued - Preclinical for Diabetic retinopathy in Norway (Parenteral) before January 2021 (Serodus' pipeline, January 2021)
- 20 Jan 2021 Preclinical trials in Diabetic nephropathies in Norway (Parenteral) before January 2021 (Serodus' pipeline, January 2021)